In terms of IL-6 on treatment, sorafenib and combination therapies are suitable for HCC cells with low or no IL-6 expression because of its augmented anti-proliferation effect and attenuated side pro-invasion by the single treatment; however, the low cell apoptosis of the combination therapy in cell with low or no IL-6 expression may counteract the application of combination treatment. This evidence concerns the gene IL6 and hepatocellular carcinoma.